LANCE ALSTODT - 06 Oct 2025 Form 4 Insider Report for BioRestorative Therapies, Inc. (BRTX)

Role
President, CEO, COB, Director, 10%+ Owner
Signature
/s/ Lance Alstodt
Issuer symbol
BRTX
Transactions as of
06 Oct 2025
Transactions value $
$25,000
Form type
4
Filing time
20 Oct 2025, 08:02:27 UTC
Previous filing
19 Feb 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
ALSTODT LANCE President, CEO, COB, Director, 10%+ Owner BIORESTORATIVE THERAPIES, INC., 40 MARCUS DRIVE, SUITE 1, MELVILLE /s/ Lance Alstodt 17 Oct 2025 0001756228

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BRTX Common Stock Award $25,000 +15,625 +9.09% $1.6 187,497 06 Oct 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BRTX Warrant Award $0 +11,719 $0 11,719 06 Oct 2025 Common Stock 11,719 $2.75 Direct
holding BRTX Stock Option 293,479 06 Oct 2025 Common Stock 293,479 $5.08 Direct F1
holding BRTX Stock Option 42,059 06 Oct 2025 Common Stock 42,059 $5.08 Direct F1
holding BRTX Stock Option 106,762 06 Oct 2025 Common Stock 106,762 $2.91 Direct F2
holding BRTX Stock Option 438,596 06 Oct 2025 Common Stock 438,596 $1.45 Direct F3
holding BRTX Stock Option 791,885 06 Oct 2025 Common Stock 791,885 $2.46 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option is currently exercisable.
F2 The option vests and becomes exercisable to the extent of 53,381 shares on February 17, 2023 and 53,381 shares in eight nearly equal quarterly installments beginning February 17, 2024 and continuing every three months thereafter until fully vested.
F3 The option vests and becomes exercisable to the extent of 219,298 shares on February 13, 2024 and 219,298 shares in eight nearly equal quarterly installments beginning February 13, 2025 and continuing every three months thereafter until fully vested.
F4 The options vests and becomes exercisable to the extent of 395,943 shares on February 14, 2025 and 395,942 shares in eight nearly equal quarterly installments beginning February 14, 2026 and continuing every three months thereafter until fully vested.